BRAF and melanoma: Future development of WEE1 ‛epigenetic inhibitor’ could facilitate specific targeting of many of WT BRAF melanomas, GBMs, triple negative breast cancers (TNBCs) and castration resistant prostate (CRPCs), which currently have a few therapeutic options.